论文部分内容阅读
目的：探讨多索茶碱治疗慢性阻塞性肺疾病的效果及安全性。方法112例慢性阻塞性肺疾病患者随机分为治疗组和对照组,治疗组和对照组均给予吸氧、抗炎、祛痰及对症支持治疗,治疗组采用多索茶碱0.3静脉滴注,qd治疗,对照组采用氨茶碱0.25静脉滴注,qd治疗,观察两组的疗效,肺功能及不良反应情况。结果治疗组总有效率94.74%,平均FEV1/FVC81.36%±6.28%,无不良反应发生；对照组总有效率85.45%,平均FEV1/FVC73.69%±5.73%,出现手抖,精神亢奋不良反应2例,发生率3.64%。两组疗效、FEV1/FVC级不良反应均存在统计学差异(<0.05)。结论多索茶碱治疗慢性阻塞性肺疾病安全有效,值得推广。“,”Objective Effect and safety of doxofylline in the treatment of chronic obstructive pulmonary disease.Methods 112 cases of chronic obstructive pulmonary disease patients were randomly divided into treatment group and control group. The treatment group and the control group were treated with oxygen, anti-inflammatory, expectorant and symptomatic and supportive treatment, the treatment group with doxofylline 0.3 intravenous drip, QD treatment, control group with aminophylline 0.25 intravenous drip, QD treatment. Observed the curative effect of the two groups, pulmonary function and adverse reaction.Results In the treatment group, the total effective rate of 94.74%, average FEV1/FVC81.36%±6.28%, without adverse reaction; in the control group, the total efficiency of 85.45%, average FEV1/FVC73.69%±5.73%, tremor, mental excitement adverse reactions in 2 cases, was 3.64%. There were significant differences in the efficacy and FEV1/FVC of the two groups ( P< 0.05). Conclusion Doxofylline is safe and effective in the treatment of chronic obstructive pulmonary disease, worthy of promotion.